| Literature DB >> 22363246 |
Shih-Tseng Lin1, Shang-Kwei Wang2, Chang-Yih Duh1,3.
Abstract
Chemical investigation of the Dongsha Atoll soft coral Lobophytum crassum has afforded four new cembranoids, crassumols A-C (1-3) and 13-acetoxysarcophytoxide (4). The structures of these isolated compounds were elucidated by extensive NMR and HRESIMS experiments. The cytotoxicity and anti-HCMV (Human cytomegalovirus) activities of 1-4 were evaluated in vitro. Compound 4 exhibited cytotoxicity against A-549 (human lung carcinoma) cell line with an ED(50) of 3.6 μg/mL.Entities:
Keywords: Lobophytum crassum; cytotoxicity; soft coral
Mesh:
Substances:
Year: 2011 PMID: 22363246 PMCID: PMC3280576 DOI: 10.3390/md9122705
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 6.085
Figure 1Soft coral Lobophytum crassum.
Figure 2The structures of compounds 1–4.
1H NMR data for compounds 1–4.
| 1 | 2 | 3 | 4 | |
|---|---|---|---|---|
| 2 | 5.79 d (15.6) | 5.51 d (9.6) | 5.53 d (10.4) | 5.60 d (11.8) |
| 3 | 5.92 d (15.6) | 5.59 d (9.6) | 5.03 d (10.4) | 5.23 d (11.8) |
| 5a | 1.94 ddd (13.2, 8.0, 2.0) | 2.48 m | 2.15 m | 2.34 m |
| 5b | 1.67 m | 2.30 m | 1.93 m | 2.36 m |
| 6a | 1.67 m | 2.42 m | 1.92 m | 2.96 m |
| 6b | 2.27 m | 1.84 m | 1.82 m | 1.63 m |
| 7 | 5.32 t (8.0) | 3.53 dd (10.8, 2.8) | 5.04 d (10.0) | 2.59 t (4.0) |
| 9a | 2.13 m | 2.16 m | 1.87 m | 2.15 ddd (13.2, 4.8, 2.8) |
| 9b | 1.97 m | 2.00 m | 1.60 m | 0.92 td (13.2, 3.2) |
| 10a | 2.06 m | 2.20 m | 2.23 m | 2.27 m |
| 10b | 2.08 m | 1.78 m | 2.06 m | 1.92 m |
| 11 | 5.22 dd (9.4, 4.8) | 3.74 d (12.0) | 4.89 br d (8.0) | 5.41 d (10.8, 5.2) |
| 13a | 2.22 m | 2.22 m | 1.97 m | 5.16 d (9.2) |
| 13b | 2.07 m | 1.78 m | 1.87 m | |
| 14a | 2.12 m | 2.64 dt (13.2, 9.8) | 2.57 ddd (14.0, 11.6, 8.0) | 2.75 dd (14.8, 10.4) |
| 14b | 1.71 m | 2.07 m | 2.14 m | 1.87 m |
| 16 | 1.07 s | 4.57 dq (15.2, 4.8) | 4.48 m | 4.49 br s |
| 17 | 1.12 s | 1.59 s | 1.65 s | 1.66 s |
| 18 | 1.25 s | 1.82 s | 1.87 s | 1.91 s |
| 19 | 1.59 s | 1.45 s | 1.09 s | 1.28 s |
| 20 | 1.64 s | 1.48 s | 1.65 s | 1.61 s |
| OH-1 | 2.52 s | |||
| OH-4 | 3.58 s | |||
| OH-15 | 3.03 s | |||
| OAc | 2.11 s | 2.00 s |
Spectra were measured in CDCl3 (400 MHz); J values (in Hz) in parentheses.
13C NMR data of compounds 1–4.
| 1 | 2 | 3 | 4 | |
|---|---|---|---|---|
| 1 | 81.5 (qC) | 126.8 (qC) | 134.1 (qC) | 130.8 (qC) |
| 2 | 128.3 (CH) | 85.1 (CH) | 83.8 (CH) | 83.3 (CH) |
| 3 | 139.1 (CH) | 126.7 (CH) | 127.6 (CH) | 126.1 (CH) |
| 4 | 73.7 (qC) | 137.6 (qC) | 137.9 (qC) | 140.2 (qC) |
| 5 | 45.3 (CH2) | 35.8 (CH2) | 35.6 (CH2) | 37.7 (CH2) |
| 6 | 24.1 (CH2) | 24.2 (CH2) | 24.8 (CH2) | 25.1 (CH2) |
| 7 | 129.0 (CH) | 83.7 (CH) | 77.3 (CH) | 61.7 (CH) |
| 8 | 133.2 (qC) | 68.3 (qC) | 75.3 (qC) | 59.5 (qC) |
| 9 | 39.9 (CH2) | 40.9 (CH2) | 37.4 (CH2) | 39.7 (CH2) |
| 10 | 24.4 (CH2) | 23.2 (CH2) | 23.7 (CH2) | 23.2 (CH2) |
| 11 | 126.3 (CH) | 80.5 (CH) | 123.2 (CH) | 127.4 (CH) |
| 12 | 137.0 (qC) | 71.4 (qC) | 137.1 (qC) | 134.9 (qC) |
| 13 | 36.4 (CH2) | 38.9 (CH2) | 36.6 (CH2) | 76.9 (CH) |
| 14 | 30.4 (CH2) | 17.8 (CH2) | 24.1 (CH2) | 31.4 (CH2) |
| 15 | 75.1 (qC) | 134.6 (qC) | 127.3 (qC) | 129.9 (qC) |
| 16 | 25.1 (CH3) | 77.5 (CH2) | 78.5 (CH3) | 78.3 (CH2) |
| 17 | 25.2 (CH3) | 9.1 (CH3) | 10.3 (CH3) | 10.1 (CH3) |
| 18 | 28.8 (CH3) | 15.1 (CH3) | 15.9 (CH3) | 15.7 (CH3) |
| 19 | 14.9 (CH3) | 20.1 (CH3) | 24.9 (CH3) | 16.7 (CH3) |
| 20 | 15.0 (CH3) | 23.3 (CH3) | 15.1 (CH3) | 9.9 (CH3) |
| OAc | 170.4 (qC) | 170.3 (qC) | ||
| 20.9 (CH3) | 21.1 (CH3) |
Spectra were measured in CDCl3 (100 MHz); Multiplicity are deduced by HSQC and DEPT experiments.
Figure 3Selected 1H–1H COSY (▬) and HMBC (→) correlations of 1 and 2.
Figure 4Selected NOESY correlations of 1.
Figure 5Selected NOESY correlations of 2.
Figure 6Selected 1H–1H COSY (▬) and HMBC (→) correlations of 3 and 4.
Figure 7Selected NOESY correlations of 3.
Figure 8Selected NOESY correlations of 4.
Cytotoxicity of 1–4.
| Compounds | Cell lines ED50 (µg/mL) | ||
|---|---|---|---|
| A549 | HT-29 | P-388 | |
| >50 | >50 | >50 | |
| >50 | >50 | >50 | |
| >50 | >50 | >50 | |
| 3.6 | 10 | 28 | |
| mithramycin | 0.18 | 0.21 | 0.15 |
For significant activity of pure compounds, an ED50 of ≤4.0 µg/mL is required; Positive control.
Figure 9Plausible biosynthetic pathway to compounds 2–4.